ArticleBMC microbiology2025
Expansion of the antibacterial spectrum of symmetrical amino acid-paired antifungal peptides through structural optimization.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundFungal infections often co-occur with antibiotic-resistant bacterial infections, posing clinical treatment challenges. Antimicrobial peptides (AMPs) are considered promising therapeutic alternatives due to their low potential for inducing drug resistance. This study aimed to enhance the antibacterial potency of an existing antifungal peptide through optimization, developing a dual-function peptide targeting both fungal and bacterial pathogens.
methodsWe designed peptides F1-F4 from the symmetrical amino acid-paired antifungal peptide P19 through threonine (T) substitution and hydrophobic moment (µHrel) adjustment. Then, we assessed their antifungal and antibacterial activities against reference and clinically isolated strains by minimum inhibitory concentrations (MICs), evaluated their toxicity to human red blood cells, and explored the membrane-associated mechanisms.
resultsPeptide F4 was the most promising candidate due to its potent antifungal and antibacterial activities, lack of inhibitory effect on beneficial lactobacilli at concentrations effective against pathogens, and low hemolytic activity. F4 also exhibited strong binding affinity to lipopolysaccharides (LPS) and induced bacterial membrane depolarization and permeabilization.
conclusionsOur findings demonstrated that T substitution and hydrophobic moment adjustment effectively enhanced antibacterial activity of the antifungal peptide P19, making peptide F4 a strong candidate for both fungal and bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.